Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.69 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.60 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26773167 | 0.95 | CYSLTR1 (0.65) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5AP | |
| SCHEMBL13772898 | 0.88 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5 | |
| SCHEMBL12169160 | 0.86 | PDE10A (0.64) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5 | |
| SCHEMBL13772899 | 0.85 | PDE10A (0.73) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL1423657 | 0.85 | PDE10A (0.72) | CYSLTR1CYSLTR2PDE10A | |
| SCHEMBL26773303 | 0.84 | CYSLTR1 (0.60) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5 | |
| SCHEMBL1423720 | 0.84 | PDE10A (0.61) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL10547475 | 0.83 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5 | |
| SCHEMBL26771259 | 0.83 | CYSLTR1 (0.92) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5 | |
| SCHEMBL8736559 | 0.83 | PDE10A (0.64) | CYSLTR1CYSLTR2PDE10AGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | PREC BIO THERAPEUTICS S R L (IT) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | GPBAR1, CYSLTR1, CYSLTR2 | CYSLTR1 2/4885CYSLTR2 3/4885PDE10A 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.